JP2015520608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520608A5 JP2015520608A5 JP2015507147A JP2015507147A JP2015520608A5 JP 2015520608 A5 JP2015520608 A5 JP 2015520608A5 JP 2015507147 A JP2015507147 A JP 2015507147A JP 2015507147 A JP2015507147 A JP 2015507147A JP 2015520608 A5 JP2015520608 A5 JP 2015520608A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- stroke
- cerebral ischemia
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 72
- 208000006011 Stroke Diseases 0.000 claims description 48
- 201000006474 Brain Ischemia Diseases 0.000 claims description 46
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 46
- 206010008118 cerebral infarction Diseases 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 42
- 210000002569 neuron Anatomy 0.000 claims description 39
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 230000006378 damage Effects 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 12
- 230000030833 cell death Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000034994 death Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000001537 neural effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 210000002265 sensory receptor cell Anatomy 0.000 claims description 8
- 208000028389 Nerve injury Diseases 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 230000008764 nerve damage Effects 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 230000007658 neurological function Effects 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- 239000002220 antihypertensive agent Substances 0.000 claims description 5
- 229940030600 antihypertensive agent Drugs 0.000 claims description 5
- 229940127218 antiplatelet drug Drugs 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 5
- 229960000103 thrombolytic agent Drugs 0.000 claims description 5
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims description 4
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 230000000324 neuroprotective effect Effects 0.000 claims description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 4
- 108090000312 Calcium Channels Proteins 0.000 claims description 3
- 102000003922 Calcium Channels Human genes 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000004958 brain cell Anatomy 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 6
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 230000005714 functional activity Effects 0.000 claims 2
- 208000037906 ischaemic injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000003018 neuroregenerative effect Effects 0.000 claims 2
- 229940125736 neurotransmitter release modulator Drugs 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- -1 antiplatelet agent Substances 0.000 description 1
- 210000000782 cerebellar granule cell Anatomy 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000035771 neuroregeneration Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625628P | 2012-04-17 | 2012-04-17 | |
| US61/625,628 | 2012-04-17 | ||
| PCT/US2013/036947 WO2013158748A1 (en) | 2012-04-17 | 2013-04-17 | Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017089783A Division JP2017127329A (ja) | 2012-04-17 | 2017-04-28 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520608A JP2015520608A (ja) | 2015-07-23 |
| JP2015520608A5 true JP2015520608A5 (enExample) | 2016-06-16 |
| JP6162219B2 JP6162219B2 (ja) | 2017-07-12 |
Family
ID=49384031
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507147A Expired - Fee Related JP6162219B2 (ja) | 2012-04-17 | 2013-04-17 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
| JP2017089783A Withdrawn JP2017127329A (ja) | 2012-04-17 | 2017-04-28 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
| JP2019000205A Withdrawn JP2019050832A (ja) | 2012-04-17 | 2019-01-04 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
| JP2020158408A Withdrawn JP2021000120A (ja) | 2012-04-17 | 2020-09-23 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
| JP2022080204A Pending JP2022107016A (ja) | 2012-04-17 | 2022-05-16 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017089783A Withdrawn JP2017127329A (ja) | 2012-04-17 | 2017-04-28 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
| JP2019000205A Withdrawn JP2019050832A (ja) | 2012-04-17 | 2019-01-04 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
| JP2020158408A Withdrawn JP2021000120A (ja) | 2012-04-17 | 2020-09-23 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
| JP2022080204A Pending JP2022107016A (ja) | 2012-04-17 | 2022-05-16 | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150104460A1 (enExample) |
| EP (2) | EP2838562B1 (enExample) |
| JP (5) | JP6162219B2 (enExample) |
| CN (2) | CN104379167B (enExample) |
| BR (1) | BR112014025898A2 (enExample) |
| CA (1) | CA2870625C (enExample) |
| ES (2) | ES2870717T3 (enExample) |
| IL (2) | IL235118B (enExample) |
| IN (1) | IN2014MN02274A (enExample) |
| MX (1) | MX356347B (enExample) |
| NZ (1) | NZ701278A (enExample) |
| WO (1) | WO2013158748A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060099203A1 (en) * | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
| IL292311A (en) | 2014-04-03 | 2022-06-01 | Igm Biosciences Inc | J-chain qualified |
| CA2967026A1 (en) | 2014-11-07 | 2016-05-12 | Mayo Foundation For Medical Education And Research | Treatment of neonatal hypoxia including impairments or effects thereof |
| SG11201707144VA (en) | 2015-03-04 | 2017-09-28 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| CA2999284C (en) | 2015-09-30 | 2023-06-13 | Igm Biosciences A/S | Binding molecules with modified j-chain |
| CN113035298B (zh) * | 2021-04-02 | 2023-06-20 | 南京信息工程大学 | 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法 |
| CN113444787A (zh) * | 2021-07-05 | 2021-09-28 | 中山大学附属第七医院(深圳) | 一种自闭症的脂质生物标志物及其应用 |
| CN114276418B (zh) * | 2021-12-28 | 2024-06-25 | 中国科学技术大学 | 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US7473423B2 (en) * | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| EP2287191B1 (en) * | 2000-05-10 | 2016-10-12 | Mayo Foundation For Medical Education And Research | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| CA2967294C (en) | 2003-05-16 | 2020-04-28 | Mayo Foundation For Medical Education & Research | Compositions and methods including a recombinant human mab that promotes cns remyelination |
| EP2204190A1 (en) * | 2003-07-15 | 2010-07-07 | Chugai Seiyaku Kabushiki Kaisha | IgM production by transformed cells and methods for quantifying said IgM production |
| CA2572098C (en) * | 2004-06-30 | 2015-01-27 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
| WO2006029184A2 (en) * | 2004-09-08 | 2006-03-16 | Expression Diagnostics, Inc. | Genes useful for diagnosing and monitoring inflammation related disorders |
| AU2007227251A1 (en) * | 2006-03-20 | 2007-09-27 | Amgen Fremont, Inc. | Antibodies directed to angiopoietin-like protein 4 and uses thereof |
| US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| US10202430B2 (en) * | 2007-10-18 | 2019-02-12 | Mayo Foundation For Medical Education And Research | IgM-mediated receptor clustering and cell modulation |
| PE20091969A1 (es) * | 2008-05-13 | 2010-01-15 | Genentech Inc | ANTICUERPOS ANTI-PirB |
| EP3219731A1 (en) * | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| CN104725507B (zh) * | 2010-10-19 | 2018-12-21 | 梅奥医学教育和研究基金会 | 用于治疗神经疾病的人抗体及其诊断和治疗用途 |
| CA2967026A1 (en) * | 2014-11-07 | 2016-05-12 | Mayo Foundation For Medical Education And Research | Treatment of neonatal hypoxia including impairments or effects thereof |
-
2013
- 2013-04-17 CN CN201380027368.0A patent/CN104379167B/zh not_active Expired - Fee Related
- 2013-04-17 ES ES17188389T patent/ES2870717T3/es active Active
- 2013-04-17 JP JP2015507147A patent/JP6162219B2/ja not_active Expired - Fee Related
- 2013-04-17 EP EP13778780.0A patent/EP2838562B1/en not_active Not-in-force
- 2013-04-17 IN IN2274MUN2014 patent/IN2014MN02274A/en unknown
- 2013-04-17 MX MX2014012651A patent/MX356347B/es active IP Right Grant
- 2013-04-17 WO PCT/US2013/036947 patent/WO2013158748A1/en not_active Ceased
- 2013-04-17 EP EP17188389.5A patent/EP3305323B1/en not_active Not-in-force
- 2013-04-17 NZ NZ701278A patent/NZ701278A/en not_active IP Right Cessation
- 2013-04-17 ES ES13778780.0T patent/ES2655077T3/es active Active
- 2013-04-17 CA CA2870625A patent/CA2870625C/en active Active
- 2013-04-17 BR BR112014025898A patent/BR112014025898A2/pt not_active Application Discontinuation
- 2013-04-17 CN CN201810021751.XA patent/CN108285483B/zh not_active Expired - Fee Related
- 2013-04-17 US US14/395,141 patent/US20150104460A1/en not_active Abandoned
-
2014
- 2014-10-19 IL IL235118A patent/IL235118B/en active IP Right Grant
-
2017
- 2017-04-28 JP JP2017089783A patent/JP2017127329A/ja not_active Withdrawn
-
2019
- 2019-01-04 JP JP2019000205A patent/JP2019050832A/ja not_active Withdrawn
- 2019-05-15 IL IL266658A patent/IL266658B/en active IP Right Grant
-
2020
- 2020-09-23 JP JP2020158408A patent/JP2021000120A/ja not_active Withdrawn
-
2022
- 2022-05-16 JP JP2022080204A patent/JP2022107016A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12343379B2 (en) | Interleukin-18 variants and methods of use | |
| AU2021202095B2 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| JP2014523884A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP6768728B2 (ja) | ヒト抗体ならびに神経疾患の処置のためのその診断的および治療的使用 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| JP2015530971A5 (enExample) | ||
| JP2013165711A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2017502920A5 (enExample) | ||
| JP2013539468A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2020521478A5 (enExample) | ||
| AU2018225493A1 (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| JP2016509585A5 (enExample) | ||
| CN108285483B (zh) | 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列 | |
| Lorusso et al. | Autonomic paraneoplastic neurological syndromes | |
| WO2019040617A1 (en) | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME | |
| CN115023435B (zh) | 免疫治疗化合物和方法 | |
| JP2015522562A5 (enExample) | ||
| CN108431039B (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| CN105745220A (zh) | 结合β淀粉状蛋白的环状肽及其用途 | |
| CA3158364A1 (en) | Anti-alpha-synuclein monoclonal antibodies, and methods using same |